96.20 0.00 (0.00%)
After hours: 5:45PM EST
|Bid||96.05 x 1200|
|Ask||96.48 x 800|
|Day's range||91.22 - 96.84|
|52-week range||28.00 - 131.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||120.01|
The world grapples with the expected tug-of-war between wealthy and poorer nations over vaccine supplies, paving the way for U.S. adversaries.
When the husband-and-wife team of Dr. Ugur Sahin and Dr. Ozlem Tureci started BioNTech (NASDAQ: BNTX), they envisioned a diversified European pharmaceutical company focused on cutting-edge cancer treatments. With the authorization and distribution of Comirnaty, the COVID-19 vaccine it developed with Pfizer (NYSE: PFE), the company will have all the resources it needs to pursue its goal. A current $26 billion market capitalization is pricing in plenty of vaccine success, but BioNTech still may not be getting the credit it deserves for the other drugs in its pipeline using its revolutionary new messenger RNA (mRNA) approach.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca